MetaCap

Who Owns Monte Rosa Therapeutics Stock?

NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

8.64-0.27 (-3.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
115.78%
Institutional holders
258
  • Institutions 99.4%
  • Insiders 0.6%
  • Public and other 0.0%

Who owns Monte Rosa Therapeutics stock?

Institutional investors own about 115.8% of Monte Rosa Therapeutics's shares, spread across 258 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.56% of GLUE.

The largest institutional holders are Price (T.Rowe) Associates Inc (8.61%), Blackrock Inc. (8.42%) and Vestal Point Capital, LP (8.34%). Together, the top 10 institutions control 59.9% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their GLUE positions and 5 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of GLUE

Monte Rosa Therapeutics top institutional holders
InstitutionShares% HeldChange
Price (T.Rowe) Associates Inc7.36M8.61%-17.0%
Blackrock Inc.7.19M8.42%+5.1%
Vestal Point Capital, LP7.13M8.34%+55.0%
NEA Management Company, LLC6.69M7.83%-13.0%
Baker Bros. Advisors, LP4.35M5.09%0.0%
BVF Inc.4.28M5.00%-4.1%
TCG Crossover Management, LLC3.78M4.43%-18.2%
State Street Corporation3.72M4.36%-0.3%
Vanguard Capital Management LLC3.48M4.07%+1.9%
Versant Venture Management, LLC3.18M3.72%0.0%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of GLUE

Monte Rosa Therapeutics top fund holders
FundShares% Held
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.55M2.99%
T. Rowe Price New Horizons Fund, Inc.2.23M2.61%
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.11M2.46%
iShares Trust-iShares Russell 2000 ETF1.92M2.24%
T. Rowe Price Health Sciences Fund, Inc.1.82M2.13%
T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U.1.38M1.61%
TR PRICE-Price (T.Rowe) New Horizons Trust983.09K1.15%
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund810.82K0.95%
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund785.01K0.92%
iShares Trust-iShares Russell 2000 Growth ETF694.65K0.81%

Frequently asked questions

Who is the largest shareholder of Monte Rosa Therapeutics?

Price (T.Rowe) Associates Inc is the largest institutional shareholder of GLUE, owning 8.61% of shares outstanding (7.36M shares) as of its latest 13F filing.

What percentage of Monte Rosa Therapeutics is owned by institutions?

Institutions own about 115.8% of GLUE shares and 116.4% of the public float.

How much of Monte Rosa Therapeutics do insiders own?

Insiders, such as officers and directors, own about 0.56% of GLUE shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related